title: Are anti-HIV IgAs good guys or bad guys?
abstract: An estimated 90% of all HIV transmissions occur mucosally. Immunoglobulin A (IgA) molecules are important components of mucosal fluids. In a vaccine efficacy study, in which virosomes displaying HIV gp41 antigens protected most rhesus monkeys (RMs) against simian-human immunodeficiency virus (SHIV), protection correlated with vaginal IgA capable of blocking HIV transcytosis in vitro. Furthermore, vaginal IgG exhibiting virus neutralization and/or antibody-dependent cellular cytotoxicity (ADCC) correlated with prevention of systemic infection. In contrast, plasma IgG had neither neutralizing nor ADCC activity. More recently, a passive mucosal immunization study provided the first direct proof that dimeric IgAs (dIgAs) can prevent SHIV acquisition in RMs challenged mucosally. This study compared dimeric IgA1 (dIgA1), dIgA2, or IgG1 versions of a human neutralizing monoclonal antibody (nmAb) targeting a conserved HIV Env epitope. While the nmAb neutralization profiles were identical in vitro, dIgA1 was significantly more protective in vivo than dIgA2. Protection was linked to a new mechanism: virion capture. Protection also correlated with inhibition of transcytosis of cell-free virus in vitro. While both of these primate model studies demonstrated protective effects of mucosal IgAs, the RV144 clinical trial identified plasma IgA responses to HIV Env as risk factors for increased HIV acquisition. In a secondary analysis of RV144, plasma IgA decreased the in vitro ADCC activity of vaccine-induced, Env-specific IgG with the same epitope specificity. Here we review the current literature regarding the potential of IgA - systemic as well as mucosal - in modulating virus acquisition and address the question whether anti-HIV IgA responses could help or harm the host.
authors.affiliation: Department of Virology & Immunology, Texas Biomedical Research Institute, 7620 NW Loop 410, San Antonio, TX, 78227, USA. mzhou@txbiomed.org.
authors.forename: Mingkui
authors.initials: M
authors.lastname: Zhou
authors.affiliation: Department of Virology & Immunology, Texas Biomedical Research Institute, 7620 NW Loop 410, San Antonio, TX, 78227, USA. rruprecht@txbiomed.org.|Southwest National Primate Research Center, 7620 NW Loop 410, San Antonio, TX, 78227, USA. rruprecht@txbiomed.org.
authors.forename: Ruth M
authors.initials: RM
authors.lastname: Ruprecht
mesh_terms: D000818:Animals; D019067:Antibody-Dependent Enhancement; D035843:Biomedical Research / Q000639:trends; D015483:HIV Antibodies / Q000378:metabolism*; D015658:HIV Infections / Q000276:immunology*; D006801:Humans; D018928:Immunity, Mucosal; D007070:Immunoglobulin A / Q000378:metabolism*; D007155:Immunologic Factors / Q000378:metabolism*; D008253:Macaca mulatta
chemical_list: D015483:HIV Antibodies; D007070:Immunoglobulin A; D007155:Immunologic Factors